No profile data available.
Evommune, Inc. (EVMN) is a listed company, based in Palo Alto, United States, with about 48 full-time employees.
It reported revenue of $13.00 million for fiscal year 2025, and net income of -$68.87 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $226.83 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Evommune reported $13.00 million in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$226.83 million as of October 9, 2026.